BES_Mark.jpg
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SpaceMobile, Rivian, and Compass Minerals and Encourages Investors to Contact the Firm
May 12, 2024 21:00 ET | Bragar Eagel & Squire
NEW YORK, May 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of...
BES_Mark.jpg
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SpaceMobile, Rivian, Compass Minerals, and Malibu Boats and Encourages Investors to Contact the Firm
May 08, 2024 21:00 ET | Bragar Eagel & Squire
NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of...
BES_Mark.jpg
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SpaceMobile, Rivian, Compass Minerals, and Malibu Boats and Encourages Investors to Contact the Firm
May 04, 2024 21:00 ET | Bragar Eagel & Squire
NEW YORK, May 04, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of...
BES_Mark.jpg
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SpaceMobile, Rivian, and Compass Minerals and Encourages Investors to Contact the Firm
April 30, 2024 21:00 ET | Bragar Eagel & Squire
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
BES_Mark.jpg
COMPASS MINERALS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Compass Minerals International, Inc. and Encourages Investors to Contact the Firm
April 26, 2024 21:00 ET | Bragar Eagel & Squire
NEW YORK, April 26, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against...
Compass-logo-RGB-outlines.png
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
April 16, 2024 08:00 ET | Compass Therapeutics
The first patient was dosed in the Phase 1 dose escalation trial of CTX-8371.This study is conducted in patients with advanced solid tumors who progressed on at least one prior regimen containing a...
Compass-logo-RGB-outlines.png
Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
February 29, 2024 08:00 ET | Compass Therapeutics
BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass-logo-RGB-outlines.png
Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial
February 28, 2024 08:00 ET | Compass Therapeutics
CTX-8371, a bispecific checkpoint inhibitor that simultaneously targets PD-1 and PD-L1, exhibits a novel mechanism-of-action leading to proteolytic cleavage and subsequent loss of cell surface...
Picture1.png
Titan Environmental Solutions Inc. Announces Agreement to Purchase Standard Waste Services, LLC
January 16, 2024 08:00 ET | Titan Environmental Solutions Inc.
Troy, MI, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Titan Environmental Solutions Inc. ("Titan" or the "Company") (OTCQB: TESI) announced today that the Company signed a Membership Interest Purchase...
Compass-logo-RGB-outlines.png
Compass Therapeutics Provides Corporate Update
January 05, 2024 08:00 ET | Compass Therapeutics
We continue to open clinical sites and enroll patients in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer...